Etiology, management, and outcome of the Budd-Chiari syndrome

Sarwa Darwish Murad, Aurelie Plessier, Manuel Hernandez-Guerra, Federica Fabris, Chundamannil E. Eapen, Matthias J. Bahr, Jonel Trebicka, Isabelle Morard, Luc Lasser, Joerg Heller, Antoine Hadengue, Philippe Langlet, Helena Miranda, Massimo Primignani, Elwyn Elias, Frank W. Leebeek, Frits R. Rosendaal, Juan Carlos Garcia-Pagan, Dominique C. Valla, Harry L A Janssen

Research output: Contribution to journalArticle

282 Citations (Scopus)

Abstract

Background: The Budd-Chiari syndrome (BCS) is hepatic venous outflow obstruction. What is known about the syndrome is based on small studies of prevalent cases. Objective: To characterize the causes and treatment of incident BCS. Design: Consecutive case series of patients with incident BCS, enrolled from October 2003 to October 2005 and followed until May 2006. Setting: Academic and nonacademic hospitals in France, Spain, Italy, Great Britain, Germany, Belgium, the Netherlands, Portugal, and Switzerland. Patients: Persons older than 16 years with definite hepatic outflow obstruction diagnosed by imaging. Persons with hepatic outflow obstruction due to heart failure, sinusoidal obstruction syndrome, cancer, or liver transplantation were excluded. Measurements: Signs and symptoms; laboratory and imaging findings; diagnosis; treatment; and overall, transplantation-free, and intervention-free survival. Results: 163 incident cases of BCS were identified. Median follow-up was 17 months (range, 0.1 to 31 months). Most patients (84%) had at least 1 thrombotic risk factor, and many (46%) had more than 1; the most common was myeloproliferative disorders (49% of 103 tested patients). Patients were mainly treated with anticoagulation (140 patients [86%]), transjugular intrahepatic portosystemic shunting (56 patients [34%]), or liver transplantation (20 patients [12%]), and 80 patients (49%) were managed noninvasively. Only 3 patients underwent surgical shunting. The survival rate was 87% (95% CI, 82% to 93%) at 1 year and 82% (CI, 75% to 88%) at 2 years. Limitation: Treatment was not standardized across all centers, and data on important clinical variables were missing for some patients. Conclusion: Most patients with BCS have at least 1 thrombotic risk factor, and many have more than 1; myeloproliferative disorders are most common. One- and 2-year survival rates are good with contemporary management, which includes noninvasive therapies (anticoagulation and diuretics) and invasive techniques. Transjugular intrahepatic portosystemic shunting seems to have replaced surgical shunting as the most common invasive therapeutic procedure. Primary Funding Source: Fifth Framework Programme of the European Commission.

Original languageEnglish
Pages (from-to)167-175
Number of pages9
JournalAnnals of Internal Medicine
Volume151
Issue number3
Publication statusPublished - Aug 4 2009

Fingerprint

Budd-Chiari Syndrome
Myeloproliferative Disorders
Liver Transplantation
Survival Rate
Hepatic Veno-Occlusive Disease
Therapeutics
Portugal
Liver
Belgium
Liver Neoplasms
Switzerland
Diuretics
Netherlands
Spain
Italy
Signs and Symptoms
France
Germany

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Murad, S. D., Plessier, A., Hernandez-Guerra, M., Fabris, F., Eapen, C. E., Bahr, M. J., ... Janssen, H. L. A. (2009). Etiology, management, and outcome of the Budd-Chiari syndrome. Annals of Internal Medicine, 151(3), 167-175.

Etiology, management, and outcome of the Budd-Chiari syndrome. / Murad, Sarwa Darwish; Plessier, Aurelie; Hernandez-Guerra, Manuel; Fabris, Federica; Eapen, Chundamannil E.; Bahr, Matthias J.; Trebicka, Jonel; Morard, Isabelle; Lasser, Luc; Heller, Joerg; Hadengue, Antoine; Langlet, Philippe; Miranda, Helena; Primignani, Massimo; Elias, Elwyn; Leebeek, Frank W.; Rosendaal, Frits R.; Garcia-Pagan, Juan Carlos; Valla, Dominique C.; Janssen, Harry L A.

In: Annals of Internal Medicine, Vol. 151, No. 3, 04.08.2009, p. 167-175.

Research output: Contribution to journalArticle

Murad, SD, Plessier, A, Hernandez-Guerra, M, Fabris, F, Eapen, CE, Bahr, MJ, Trebicka, J, Morard, I, Lasser, L, Heller, J, Hadengue, A, Langlet, P, Miranda, H, Primignani, M, Elias, E, Leebeek, FW, Rosendaal, FR, Garcia-Pagan, JC, Valla, DC & Janssen, HLA 2009, 'Etiology, management, and outcome of the Budd-Chiari syndrome', Annals of Internal Medicine, vol. 151, no. 3, pp. 167-175.
Murad SD, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Annals of Internal Medicine. 2009 Aug 4;151(3):167-175.
Murad, Sarwa Darwish ; Plessier, Aurelie ; Hernandez-Guerra, Manuel ; Fabris, Federica ; Eapen, Chundamannil E. ; Bahr, Matthias J. ; Trebicka, Jonel ; Morard, Isabelle ; Lasser, Luc ; Heller, Joerg ; Hadengue, Antoine ; Langlet, Philippe ; Miranda, Helena ; Primignani, Massimo ; Elias, Elwyn ; Leebeek, Frank W. ; Rosendaal, Frits R. ; Garcia-Pagan, Juan Carlos ; Valla, Dominique C. ; Janssen, Harry L A. / Etiology, management, and outcome of the Budd-Chiari syndrome. In: Annals of Internal Medicine. 2009 ; Vol. 151, No. 3. pp. 167-175.
@article{f9ed6a8967b64860b6f6f741947559d2,
title = "Etiology, management, and outcome of the Budd-Chiari syndrome",
abstract = "Background: The Budd-Chiari syndrome (BCS) is hepatic venous outflow obstruction. What is known about the syndrome is based on small studies of prevalent cases. Objective: To characterize the causes and treatment of incident BCS. Design: Consecutive case series of patients with incident BCS, enrolled from October 2003 to October 2005 and followed until May 2006. Setting: Academic and nonacademic hospitals in France, Spain, Italy, Great Britain, Germany, Belgium, the Netherlands, Portugal, and Switzerland. Patients: Persons older than 16 years with definite hepatic outflow obstruction diagnosed by imaging. Persons with hepatic outflow obstruction due to heart failure, sinusoidal obstruction syndrome, cancer, or liver transplantation were excluded. Measurements: Signs and symptoms; laboratory and imaging findings; diagnosis; treatment; and overall, transplantation-free, and intervention-free survival. Results: 163 incident cases of BCS were identified. Median follow-up was 17 months (range, 0.1 to 31 months). Most patients (84{\%}) had at least 1 thrombotic risk factor, and many (46{\%}) had more than 1; the most common was myeloproliferative disorders (49{\%} of 103 tested patients). Patients were mainly treated with anticoagulation (140 patients [86{\%}]), transjugular intrahepatic portosystemic shunting (56 patients [34{\%}]), or liver transplantation (20 patients [12{\%}]), and 80 patients (49{\%}) were managed noninvasively. Only 3 patients underwent surgical shunting. The survival rate was 87{\%} (95{\%} CI, 82{\%} to 93{\%}) at 1 year and 82{\%} (CI, 75{\%} to 88{\%}) at 2 years. Limitation: Treatment was not standardized across all centers, and data on important clinical variables were missing for some patients. Conclusion: Most patients with BCS have at least 1 thrombotic risk factor, and many have more than 1; myeloproliferative disorders are most common. One- and 2-year survival rates are good with contemporary management, which includes noninvasive therapies (anticoagulation and diuretics) and invasive techniques. Transjugular intrahepatic portosystemic shunting seems to have replaced surgical shunting as the most common invasive therapeutic procedure. Primary Funding Source: Fifth Framework Programme of the European Commission.",
author = "Murad, {Sarwa Darwish} and Aurelie Plessier and Manuel Hernandez-Guerra and Federica Fabris and Eapen, {Chundamannil E.} and Bahr, {Matthias J.} and Jonel Trebicka and Isabelle Morard and Luc Lasser and Joerg Heller and Antoine Hadengue and Philippe Langlet and Helena Miranda and Massimo Primignani and Elwyn Elias and Leebeek, {Frank W.} and Rosendaal, {Frits R.} and Garcia-Pagan, {Juan Carlos} and Valla, {Dominique C.} and Janssen, {Harry L A}",
year = "2009",
month = "8",
day = "4",
language = "English",
volume = "151",
pages = "167--175",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Etiology, management, and outcome of the Budd-Chiari syndrome

AU - Murad, Sarwa Darwish

AU - Plessier, Aurelie

AU - Hernandez-Guerra, Manuel

AU - Fabris, Federica

AU - Eapen, Chundamannil E.

AU - Bahr, Matthias J.

AU - Trebicka, Jonel

AU - Morard, Isabelle

AU - Lasser, Luc

AU - Heller, Joerg

AU - Hadengue, Antoine

AU - Langlet, Philippe

AU - Miranda, Helena

AU - Primignani, Massimo

AU - Elias, Elwyn

AU - Leebeek, Frank W.

AU - Rosendaal, Frits R.

AU - Garcia-Pagan, Juan Carlos

AU - Valla, Dominique C.

AU - Janssen, Harry L A

PY - 2009/8/4

Y1 - 2009/8/4

N2 - Background: The Budd-Chiari syndrome (BCS) is hepatic venous outflow obstruction. What is known about the syndrome is based on small studies of prevalent cases. Objective: To characterize the causes and treatment of incident BCS. Design: Consecutive case series of patients with incident BCS, enrolled from October 2003 to October 2005 and followed until May 2006. Setting: Academic and nonacademic hospitals in France, Spain, Italy, Great Britain, Germany, Belgium, the Netherlands, Portugal, and Switzerland. Patients: Persons older than 16 years with definite hepatic outflow obstruction diagnosed by imaging. Persons with hepatic outflow obstruction due to heart failure, sinusoidal obstruction syndrome, cancer, or liver transplantation were excluded. Measurements: Signs and symptoms; laboratory and imaging findings; diagnosis; treatment; and overall, transplantation-free, and intervention-free survival. Results: 163 incident cases of BCS were identified. Median follow-up was 17 months (range, 0.1 to 31 months). Most patients (84%) had at least 1 thrombotic risk factor, and many (46%) had more than 1; the most common was myeloproliferative disorders (49% of 103 tested patients). Patients were mainly treated with anticoagulation (140 patients [86%]), transjugular intrahepatic portosystemic shunting (56 patients [34%]), or liver transplantation (20 patients [12%]), and 80 patients (49%) were managed noninvasively. Only 3 patients underwent surgical shunting. The survival rate was 87% (95% CI, 82% to 93%) at 1 year and 82% (CI, 75% to 88%) at 2 years. Limitation: Treatment was not standardized across all centers, and data on important clinical variables were missing for some patients. Conclusion: Most patients with BCS have at least 1 thrombotic risk factor, and many have more than 1; myeloproliferative disorders are most common. One- and 2-year survival rates are good with contemporary management, which includes noninvasive therapies (anticoagulation and diuretics) and invasive techniques. Transjugular intrahepatic portosystemic shunting seems to have replaced surgical shunting as the most common invasive therapeutic procedure. Primary Funding Source: Fifth Framework Programme of the European Commission.

AB - Background: The Budd-Chiari syndrome (BCS) is hepatic venous outflow obstruction. What is known about the syndrome is based on small studies of prevalent cases. Objective: To characterize the causes and treatment of incident BCS. Design: Consecutive case series of patients with incident BCS, enrolled from October 2003 to October 2005 and followed until May 2006. Setting: Academic and nonacademic hospitals in France, Spain, Italy, Great Britain, Germany, Belgium, the Netherlands, Portugal, and Switzerland. Patients: Persons older than 16 years with definite hepatic outflow obstruction diagnosed by imaging. Persons with hepatic outflow obstruction due to heart failure, sinusoidal obstruction syndrome, cancer, or liver transplantation were excluded. Measurements: Signs and symptoms; laboratory and imaging findings; diagnosis; treatment; and overall, transplantation-free, and intervention-free survival. Results: 163 incident cases of BCS were identified. Median follow-up was 17 months (range, 0.1 to 31 months). Most patients (84%) had at least 1 thrombotic risk factor, and many (46%) had more than 1; the most common was myeloproliferative disorders (49% of 103 tested patients). Patients were mainly treated with anticoagulation (140 patients [86%]), transjugular intrahepatic portosystemic shunting (56 patients [34%]), or liver transplantation (20 patients [12%]), and 80 patients (49%) were managed noninvasively. Only 3 patients underwent surgical shunting. The survival rate was 87% (95% CI, 82% to 93%) at 1 year and 82% (CI, 75% to 88%) at 2 years. Limitation: Treatment was not standardized across all centers, and data on important clinical variables were missing for some patients. Conclusion: Most patients with BCS have at least 1 thrombotic risk factor, and many have more than 1; myeloproliferative disorders are most common. One- and 2-year survival rates are good with contemporary management, which includes noninvasive therapies (anticoagulation and diuretics) and invasive techniques. Transjugular intrahepatic portosystemic shunting seems to have replaced surgical shunting as the most common invasive therapeutic procedure. Primary Funding Source: Fifth Framework Programme of the European Commission.

UR - http://www.scopus.com/inward/record.url?scp=68249099452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68249099452&partnerID=8YFLogxK

M3 - Article

C2 - 19652186

AN - SCOPUS:68249099452

VL - 151

SP - 167

EP - 175

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -